AcelRx Pharmaceuticals Provides Guidance on 2017 Milestones for ARX-04, now known as DSUVIA™ in the United States, for the Treatment of Moderate-to-Severe Acute Pain Life Science Investing
Cancer Genetics, Inc. Announces Consolidation and Cost Reduction in Administrative and Operational Support Functions Medical Device Investing
VBL Therapeutics Announces Completion of Enrollment in the Pivotal GLOBE Study Life Science Investing
Adamas Announces USFDA Acceptance of New Drug Application for Levodopa-induced Dyskinesia in Patients with Parkinson's Disease Life Science Investing
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026
